| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Medtronic Plc (NYSE:MDT) on Tuesday reported strong second-quarter 2026 results.
The company’s sales reached $8.96 billion, surpassing the consensus estimate of $8.87 billion. This marks a 6.6% increase year-over-year, with organic growth of 5.5%. Adjusted earnings of $1.36 per share also beat expectations of $1.31.
"…Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic chairman and CEO.
Medtronic raised its fiscal year 2026 organic revenue growth guidance to 5.5% from 5%. The medical devices giant raised adjusted earnings for fiscal 2026 to $5.62-$5.66 per share, versus the prior $5.60-$5.66, and the consensus of $5.63.
The guidance includes a potential impact from tariffs of approximately $185 million, unchanged from the prior guidance. Excluding the potential impact from tariffs, the guidance represents fiscal 2026 diluted adjusted earnings per share growth of approximately 4.5%.
Medtronic shares fell 0.1% to trade at $100.78 on Wednesday.
These analysts made changes to their price targets on Medtronic following earnings announcement.
Considering buying MDT stock? Here’s what analysts think:

Read This Next:
Photo via Shutterstock
Posted In: MDT